Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorHaukland, Ellinor
dc.contributor.authorMannsåker, Bård
dc.contributor.authorPawinski, Adam
dc.date.accessioned2018-08-20T13:36:28Z
dc.date.available2018-08-20T13:36:28Z
dc.date.issued2017-01-25
dc.description.abstract<p><i>Background</i>: The aim of the study was to explore the prognostic impact of different abnormal blood tests and the tumor marker CA 15-3 as well as established parameters such as disease extent and receptor status in patients with bone metastases from breast cancer who received palliative radiotherapy in addition to contemporary systemic treatment.</p> <p><i>Methods</i>: This was a retrospective uni- and multivariate analysis of 118 female patients treated in the time period from 2007 to 2014 (median follow-up 28 months).</p> <p><i>Results</i>: The median age was 61 years and the median time interval from the initial diagnosis of breast cancer was 57 months (median time interval from metastatic disease to radiotherapy was 7 months). Only 16% of patients had normal serum CA 15-3. HER2 receptor status correlated with CA 15-3. The median survival was 17.6 months (lowest CA 15-3 quartile), 14.7 months (intermediate), and 6.9 months (highest quartile) (P = 0.002). However, multivariate analysis showed that survival was influenced by extent of extra-skeletal metastases, pleural metastases/effusion, lung metastases, estrogen receptor status, serum C-reactive protein, and anemia with need for blood transfusion (all P < 0.05) rather than CA 15-3.</p> <p><i>Conclusions</i>: Survival was highly variable. The tumor marker CA 15-3 did not provide independent prognostic information. Nevertheless, the results of simple blood tests contributed to the multivariate prognostic model.en_US
dc.descriptionSource at <a href=https://doi.org/10.14740/jocmr2653w> https://doi.org/10.14740/jocmr2653w</a>. Accepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0.</a>en_US
dc.identifier.citationNieder, C., Dalhaug, A., Haukland, E., Mannsåker, B. & Pawinski, A. (2017). Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. Journal of Clinical Medicine Research, 9(3), 183-187. https://doi.org/10.14740/jocmr2653wen_US
dc.identifier.cristinIDFRIDAID 1463242
dc.identifier.doi10.14740/jocmr2653w
dc.identifier.issn1918-3003
dc.identifier.issn1918-3011
dc.identifier.urihttps://hdl.handle.net/10037/13488
dc.language.isoengen_US
dc.publisherElmer Pressen_US
dc.relation.journalJournal of Clinical Medicine Research
dc.rights.accessRightsopenAccessen_US
dc.subjectBiomarkeren_US
dc.subjectBone metastasesen_US
dc.subjectBreast canceren_US
dc.subjectPrognostic factorsen_US
dc.subjectRadiotherapyen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titlePrognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapyen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record